Dabomb Protein Biotech (ROCO:6578) Cyclically Adjusted Revenue per Share: NT$16.30 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6578 Dabomb Protein Biotech Corp ROCO:6578
57 GF Score
Price NT$18.25
GF Value NT$16.58
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Dabomb Protein Biotech Cyclically Adjusted Revenue per Share?

Dabomb Protein Biotech ROCO:6578 +9.94% 57 Cyclically Adjusted Revenue per Share is NT$16.30 as of Mar. 2026. GuruFocus rates ROCO:6578 with a GF Score™ of 57/100 and a GF Value™ of NT$16.58 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Dabomb Protein Biotech's adjusted revenue per share for the three months ended in Mar. 2026 was NT$1.141. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$16.30 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-05), Dabomb Protein Biotech's current stock price is NT$18.25. Dabomb Protein Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$16.30. Dabomb Protein Biotech's Cyclically Adjusted PS Ratio of today is 1.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dabomb Protein Biotech was 1.26. The lowest was 0.93. And the median was 1.12.


Dabomb Protein Biotech  (ROCO:6578) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dabomb Protein Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=18.25/16.30
=1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dabomb Protein Biotech was 1.26. The lowest was 0.93. And the median was 1.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Dabomb Protein Biotech Cyclically Adjusted Revenue per Share Related Terms


Dabomb Protein Biotech Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Dabomb Protein Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dabomb Protein Biotech Cyclically Adjusted Revenue per Share Chart

Dabomb Protein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 16.32

Dabomb Protein Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 16.70 16.32 16.30

ROCO:6578 vs KHC, GIS: Cyclically Adjusted Revenue per Share Comparison

For the Packaged Foods subindustry, Dabomb Protein Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dabomb Protein Biotech Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dabomb Protein Biotech's Cyclically Adjusted PS Ratio falls into.


ROCO:6578
57GF Score
Dabomb Protein Biotech Corp ROCO:6578
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dabomb Protein Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dabomb Protein Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.141/330.2130*330.2130
=1.141

Current CPI (Mar. 2026) = 330.2130.

Dabomb Protein Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 236.525 0.000
201606 0.000 241.018 0.000
201612 0.000 241.432 0.000
201703 3.980 243.801 5.391
201706 5.226 244.955 7.045
201709 5.188 246.819 6.941
201712 5.234 246.524 7.011
201803 5.273 249.554 6.977
201806 5.385 251.989 7.057
201809 5.222 252.439 6.831
201812 4.677 251.233 6.147
201903 4.577 254.202 5.946
201906 5.657 256.143 7.293
201909 5.628 256.759 7.238
201912 3.808 256.974 4.893
202003 3.278 258.115 4.194
202006 4.716 257.797 6.041
202009 4.707 260.280 5.972
202012 5.595 260.474 7.093
202103 3.984 264.877 4.967
202106 3.289 271.696 3.997
202109 3.299 274.310 3.971
202112 3.889 278.802 4.606
202203 3.074 287.504 3.531
202206 2.989 296.311 3.331
202209 2.208 296.808 2.457
202212 2.928 296.797 3.258
202303 2.518 301.836 2.755
202306 1.735 305.109 1.878
202309 1.473 307.789 1.580
202312 1.685 306.746 1.814
202403 1.409 312.332 1.490
202406 1.500 314.175 1.577
202409 0.755 315.301 0.791
202412 1.137 315.605 1.190
202503 0.954 319.799 0.985
202506 1.291 322.561 1.322
202509 0.949 324.800 0.965
202512 1.124 324.054 1.145
202603 1.141 330.213 1.141

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$16.30 mean?
Dabomb Protein Biotech (ROCO:6578) has a Cyclically Adjusted Revenue per Share of NT$16.30 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dabomb Protein Biotech and its competitors.
Is Dabomb Protein Biotech's Cyclically Adjusted Revenue per Share too high?
Dabomb Protein Biotech's current Cyclically Adjusted Revenue per Share is NT$16.30. Overall, Dabomb Protein Biotech has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Cyclically Adjusted Revenue per Share compare to KHC and GIS?
Dabomb Protein Biotech's Cyclically Adjusted Revenue per Share of NT$16.30 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dabomb Protein Biotech and its competitors. Dabomb Protein Biotech's current Cyclically Adjusted Revenue per Share is NT$16.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$16.58, compared to a current price of NT$18.25 — trading 10.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$16.30. Dabomb Protein Biotech's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Cyclically Adjusted Revenue per Share is NT$16.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?

Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued. The current stock price of NT$18.25 is trading 10.1% above its estimated GF Value™ of NT$16.58. GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.

Key valuation signals for ROCO:6578:

  • Cyclically Adjusted Revenue per Share: NT$16.30
  • GF Value™: NT$16.58 vs. price of NT$18.25 (10.1% above fair value)
  • GF Score™: 57/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dabomb Protein Biotech Business Description

Address No. 52, Industrial 3rd Road, Annan District, Tainan, TWN, 709
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
57GF Score

Get the complete analysis for ROCO:6578

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.25
Price
NT$16.58
GF Value